Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind Study
Open Access
- 1 October 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (7) , 1015-1021
- https://doi.org/10.1086/322694
Abstract
Concerns about the tolerability of mefloquine highlight the need for new drugs to prevent malaria. Atovaquone-proguanil (Malarone; GlaxoSmithKline) wKeywords
This publication has 24 references indexed in Scilit:
- Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind studyThe Lancet, 2000
- Health Advice and Immunizations for TravelersNew England Journal of Medicine, 2000
- Neuropsychiatric Adverse Effects of MefloquineCNS Drugs, 1999
- Lesson of the week: Malaria at Christmas: risks of prophylaxis versus risks of malariaBMJ, 1998
- Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in childrenThe Lancet, 1998
- Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trialTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellersBMJ, 1996
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINEThe Lancet, 1987
- Paper: Researches on paludrine (M.4888) in Malaria An experimental investigation undetaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, AustraliaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1946